Skip to Content

Generic Sovaldi Availability

Sovaldi is a brand name of sofosbuvir, approved by the FDA in the following formulation(s):

SOVALDI (sofosbuvir - tablet;oral)

  • Manufacturer: GILEAD SCIENCES INC
    Approval date: December 6, 2013
    Strength(s): 400MG [RLD]

Has a generic version of Sovaldi been approved?

No. There is currently no therapeutically equivalent version of Sovaldi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sovaldi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Nucleoside phosphoramidate prodrugs
    Patent 7,964,580
    Issued: June 21, 2011
    Inventor(s): Sofia; Michael Joseph & Du; Jinfa & Wang; Peiyuan
    Assignee(s): Pharmasset, Inc.
    Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Patent expiration dates:
    • March 26, 2029
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Nucleoside phosphoramidate prodrugs
    Patent 8,334,270
    Issued: December 18, 2012
    Inventor(s): Sofia; Michael Joseph & Du; Jinfa & Wang; Peiyuan & Nagarathnam; Dhanapalan
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Nucleoside phosphoramidate prodrugs
    Patent 8,580,765
    Issued: November 12, 2013
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Nucleoside phosphoramidates
    Patent 8,618,076
    Issued: December 31, 2013
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Patent expiration dates:
    • December 11, 2030
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Nucleoside phosphoramidates
    Patent 8,633,309
    Issued: January 21, 2014
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Patent expiration dates:
    • March 26, 2029
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compositions and methods for treating hepatitis C virus
    Patent 8,889,159
    Issued: November 18, 2014
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Patent expiration dates:
    • March 26, 2029
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug product
  • Nucleoside phosphoramidate prodrugs
    Patent 9,085,573
    Issued: July 21, 2015
    Assignee(s): GILEAD PHARMASSET LLC
    Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Nucleoside phosphoramidates
    Patent 9,284,342
    Issued: March 15, 2016
    Assignee(s): Gilead Pharmasset LLC
    Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Patent expiration dates:
    • September 13, 2030
      ✓ 
      Patent use: FOR THE TREATMENT OF HEPATITIS C
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 6, 2018 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide